Drug Trial Radar · NCT02687906
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Jul 2016
Primary completion
Jul 2026
Study completion Jul 15, 2026
Sponsor
- Lead sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)Industry
- Sponsor type
- Industry
- Collaborators
- Department of Health and Human Services
- First posted
- Feb 22, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections
Conditions
- Bacterial Infections
Interventions
VabomereDrug
Vabomere (meropenem-vaborbactam) for IV injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics: AUC0-∞Time frame: From pre-dose until 6 hours after the start of the infusion
- Pharmacokinetics: CmaxTime frame: From pre-dose until 6 hours after the start of the infusion
- Pharmacokinetics: time to maximum plasma concentration (Tmax)Time frame: From pre-dose until 6 hours after the start of the infusion
- Pharmacokinetics: drug clearance (CL)Time frame: From pre-dose until 6 hours after the start of the infusion
- Pharmacokinetics: t1/2Time frame: From pre-dose until 6 hours after the start of the infusion
- Pharmacokinetics: CminTime frame: From pre-dose until 6 hours after the start of the infusion
- Pharmacokinetics: VssTime frame: From pre-dose until 6 hours after the start of the infusion
- Safety and tolerability: AEs/SAEsTime frame: From assent / consent until day 7 safety follow up call
- Safety and tolerability: clinical safety laboratory resultsTime frame: From assent / consent until day 7 safety follow up call
- Safety and tolerability: vital signsTime frame: From assent / consent until day 7 safety follow up call
- Safety and tolerability: ECGsTime frame: From assent / consent until day 7 safety follow up call
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
Ronald Reagan UCLA Medical Center
Los Angeles, California
Children's Hospital of Orange County
Orange, California
Rady Children's Hospital San Diego
San Deigo, California
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Nebraska Medical Center
Omaha, Nebraska
Rutger's University
New Brunswick, New Jersey
Rainbow Babies and Childrens Hospital
Cleveland, Ohio
Toledo Children's Hospital
Toledo, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.